We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Systemic fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate. This follows a review by the MHRA which looked at the effectiveness of current measures to reduce the identified risk of disabling and potentially long-lasting or...
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
How investigators and sponsors should manage clinical trials during COVID-19
Anyone can report an illegal medicine or prescription misuse and a company can use these forms to report a supply problem or product defect.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
A review on the extent of medication errors and recommendations to reduce medication-related harm in England.
Explains changes to drug driving law and the guidance available for healthcare professionals and users of prescription medicine.
Information for wholesale dealer licence holders about the medicines put on the UK market for UK patients that they cannot export or hoard.
Torrent Pharma (UK) Limited is recalling certain batches of Ramipril 1.25mg tablets as a precautionary measure due to these batches having a low assay and high related substances test results after their release to the market.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Legal terms for veterinary medicines, marketing of non-medicinal products including medicinal words and phrases, how to complain.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances
Novartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MHRA.
Accord Healthcare Ltd, UK has informed the MHRA about an error with the Patient Information Leaflets (PILs) that have been packaged in the batches of these products mentioned in this notification.
This guidance demonstrates stakeholders, including the government, working together to address supply issues.
How veterinary medicines can be advertised.
Information on good laboratory, manufacturing and distribution practice, good pharmacovigilance practice (GPvP), out-of-specification investigations, inspection metrics and fees.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.